OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer Therapeutics is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Selected Articles from This Issue	120
Abstract B048: Fibroblast Growth Factor Receptor 2 Alterations in non-Cholangiocarcinoma Gastrointestinal Tumors	79
Abstract C078: DNA Nanocarrier-mediated Co-Delivery of Cisplatin and Silibinin for enhanced treatment of Oral Squamous Cell Carcinoma	71
Abstract A043: P-gp overexpression confers resistance to treatment with the antibody-drug conjugate mirvetuximab soravtansine	64
Abstract A093: VRN110755 Shows Promise with Improved Efficacy in EGFR mutation NSCLC: Highlighting CNS activity, Potency Against Resistant EGFR Mutations, and a Favorable Safety Profile	64
Abstract B119: FMC-376, a dual inhibitor of ON + OFF states of KRAS G12C, is active in sotorasib resistant PDX models	63
Abstract A042: Evolution of resistance in brain tumors: Effects of the blood brain barrier	61
Abstract A014: Comprehensive genomic and clinicopathologic characterization of ESR1 mutations in Chinese breast cancer patients reveals distinct molecula	60
Abstract B073: Targeted Phenotype Shifting or Killing Tumor Associated Macropages (TAMs) Leading to Effective Upregulation of the Immune System Response to Solid Tumors: A Comprehensive	58
A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma	57
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition	55
Abstract B086: Anchored in Resistance: Overcoming Nidogen-2 (NID2) - mediated Immunoresistance in Ovarian Cancer with Ras and Bcl-xl Inhibition	54
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers	53
Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer	53
Lurbinectedin Inhibits the EWS–WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor	47
Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)	45
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer	45
Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death	42
Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer	39
Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer	39
Inhibition of DKK-1 by WAY262611 Inhibits Osteosarcoma Metastasis	38
Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFRpos Mouse Xenograft Model	35
Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors	33
Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal Tissues	33
Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer	33

IKS04, a CanAg-Targeting Antibody–Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models	31
Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabd	31
In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation	30
Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas	30
Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma	29
Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma	29